CapsoVision, IncCV

CapsoVision, Inc. wants you to know its CapsoCam Plus capsule endoscopy system is the only one offering a ‘complete 360° panoramic view’ of the gastrointestinal tract, a claim backed by a product page that reads more like a brochure than a financial statement. The device itself uses four high-resolution cameras to capture images as it travels through the small bowel, a neat trick if you can pull it off-though the company’s latest 10-Q suggests the trick isn’t paying the rent just yet. The filing shows $2.8 million in revenue for the quarter ended March 31, 2026, a figure that sounds modest until you pair it with $7 million in losses and a quarterly cash burn of $6.1 million. The device may be cutting-edge; the numbers are bluntly terrestrial.

CapsoVision styles itself as a ‘Silicon Valley global medical device innovator specialising in diagnostic imaging of the gastrointestinal system,’ a line that rolls off the tongue as smoothly as the CapsoCam Plus supposedly rolls through a patient’s digestive tract. The company’s newsroom and product pages lean into the promise of AI-enabled platforms and clinical innovation, but the balance sheet is stuck in a more prosaic reality: $25.9 million in assets, $5.7 million in liabilities, and a stockholders’ equity of $20.2 million. The gap between the polished platform story and the filed numbers is wider than a patient’s small bowel, and the company’s cash position isn’t doing the heavy lifting required to bridge it.

The 10-Q for the quarter ended March 31, 2026, tells the story in hard numbers. Revenue from contracts with customers, excluding assessed tax, clocked in at $2.8 million. Net income attributable to the parent was a loss of $7 million, operating income a loss of $7.1 million, and earnings per share (diluted) came in at -$0.15 on 47.5 million shares. Cash used in operating activities was $6.1 million, while payments to acquire property, plant, and equipment were a relatively modest $48,000. Research and development expense weighed in at $4.4 million, and inventory, net, sat at $3.5 million, up $504,000 from the prior period. The filing is a blunt instrument: it shows a company burning cash, investing in R&D, and hoping the future pays the tab.

CapsoVision’s product pages and newsroom are all gloss and promise, but the company’s operating reality is captured in the SEC filings and the numbers they contain. The CapsoCam Plus may be the only system with a 360° view, but the 10-Q shows a company with a narrow view of profitability. The device is real; the commercial ramp is not reflected in the filings, and the company’s cash burn continues to outpace its revenue growth. The contrast between the product pitch and the balance sheet is stark enough to make a gastroenterologist wince.

The source rail for this file includes the company’s product specifications, newsroom, and SEC filings, all of which confirm the device’s design and the company’s financial trajectory. The product specs detail the four-camera system, while the 10-Q and related filings lay out the financial and operational reality. The company’s newsroom and product pages frame a narrative of innovation and clinical impact, but the filings tell a different story: one of losses, cash burn, and a balance sheet that’s more ‘work in progress’ than ‘commercial success.’ The source rail does not provide guidance, segment-level breakdowns, or evidence of a near-term commercial inflection point. What it does show is a company investing heavily in R&D and production while revenue lags, a dynamic that raises questions about the pace of commercial adoption and the path to profitability.